Mustang Bio
4
0
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
75.0%
3 terminated/withdrawn out of 4 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Role: collaborator
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Role: lead
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Role: lead
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Role: lead
All 4 trials loaded